Commodore Capital
Latest statistics and disclosures from Commodore Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRUS, VERA, NUVL, XENE, SYRE, and represent 40.74% of Commodore Capital's stock portfolio.
- Added to shares of these 10 stocks: MNMD (+$55M), ORIC (+$28M), CATX (+$25M), Kyverna Therapeutics (+$23M), PHVS (+$21M), ENGN (+$21M), ELVN (+$19M), AUTL (+$15M), NUVL (+$12M), ARVN (+$11M).
- Started 12 new stock positions in CATX, Adverum Biotechnologies, MNMD, ENGN, NGNE, ORIC, AUTL, Kyverna Therapeutics, SNDX, MGNX. Helix Acquisition Corp Ii Cl A, ACET.
- Reduced shares in these 10 stocks: VERA (-$99M), Rayzebio (-$24M), SLNO (-$23M), RYTM (-$22M), MRUS (-$17M), Harpoon Therapeutics (-$17M), PCVX (-$16M), CABA (-$14M), AKRO (-$13M), DYN (-$12M).
- Sold out of its positions in Adverum Biotechnologies, AKRO, DYN, Harpoon Therapeutics, Rayzebio.
- Commodore Capital was a net buyer of stock by $4.0M.
- Commodore Capital has $1.5B in assets under management (AUM), dropping by 29.39%.
- Central Index Key (CIK): 0001831942
Tip: Access up to 7 years of quarterly data
Positions held by Commodore Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Commodore Capital
Commodore Capital holds 39 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Merus N V (MRUS) | 13.1 | $196M | -8% | 4.4M | 45.03 |
|
| Vera Therapeutics Cl A (VERA) | 9.1 | $137M | -41% | 3.2M | 43.12 |
|
| Nuvalent Inc-a (NUVL) | 7.5 | $112M | +11% | 1.5M | 75.09 |
|
| Xenon Pharmaceuticals (XENE) | 6.2 | $93M | 2.2M | 43.05 |
|
|
| Spyre Therapeutics Com New (SYRE) | 4.8 | $72M | 1.9M | 37.93 |
|
|
| Enliven Therapeutics (ELVN) | 4.7 | $70M | +36% | 4.0M | 17.59 |
|
| Vaxcyte (PCVX) | 3.9 | $59M | -21% | 860k | 68.31 |
|
| Mind Medicine Mindmed Com New (MNMD) | 3.7 | $55M | NEW | 5.8M | 9.40 |
|
| Alpine Immune Sciences (ALPN) | 3.6 | $55M | -14% | 1.4M | 39.64 |
|
| Arvinas Ord (ARVN) | 3.5 | $53M | +27% | 1.3M | 41.28 |
|
| Rhythm Pharmaceuticals (RYTM) | 3.0 | $46M | -32% | 1.1M | 43.33 |
|
| Cogent Biosciences (COGT) | 2.9 | $43M | +15% | 6.4M | 6.72 |
|
| Pharvaris N V (PHVS) | 2.7 | $40M | +115% | 1.7M | 23.11 |
|
| Celldex Therapeutics Com New (CLDX) | 2.4 | $36M | +23% | 867k | 41.97 |
|
| Nkarta (NKTX) | 2.3 | $34M | +15% | 3.2M | 10.81 |
|
| Miragen Therapeutics (VRDN) | 2.3 | $34M | 1.9M | 17.51 |
|
|
| Celcuity (CELC) | 2.2 | $34M | -11% | 1.6M | 21.60 |
|
| Kura Oncology (KURA) | 2.2 | $33M | +22% | 1.5M | 21.33 |
|
| C4 Therapeutics Com Stk (CCCC) | 1.9 | $28M | -10% | 3.4M | 8.17 |
|
| Oric Pharmaceuticals (ORIC) | 1.8 | $28M | NEW | 2.0M | 13.75 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.8 | $27M | 1.9M | 14.30 |
|
|
| IsoRay (CATX) | 1.7 | $25M | NEW | 21M | 1.19 |
|
| Immunovant (IMVT) | 1.6 | $24M | -24% | 751k | 32.31 |
|
| Kyverna Therapeutics | 1.5 | $23M | NEW | 912k | 24.84 |
|
| Engene Holdings (ENGN) | 1.4 | $21M | NEW | 1.3M | 16.95 |
|
| Apogee Therapeutics (APGE) | 1.3 | $19M | +16% | 290k | 66.45 |
|
| Cabaletta Bio (CABA) | 1.3 | $19M | -42% | 1.1M | 17.06 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.0 | $15M | NEW | 2.3M | 6.38 |
|
| Third Harmonic Bio (THRD) | 0.8 | $12M | +76% | 1.3M | 9.44 |
|
| Neurogene (NGNE) | 0.7 | $10M | NEW | 200k | 50.90 |
|
| Adverum Biotechnologies Com New | 0.6 | $9.3M | NEW | 657k | 14.14 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.6 | $8.3M | 1.6M | 5.28 |
|
|
| Syndax Pharmaceuticals (SNDX) | 0.5 | $7.6M | NEW | 319k | 23.80 |
|
| Soleno Therapeutics (SLNO) | 0.5 | $7.3M | -75% | 170k | 42.80 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs | 0.3 | $5.2M | NEW | 500k | 10.40 |
|
| Macrogenics (MGNX) | 0.3 | $4.3M | NEW | 295k | 14.72 |
|
| Adicet Bio (ACET) | 0.2 | $3.2M | NEW | 1.4M | 2.35 |
|
| Sab Biotherapeutics Com New (SABS) | 0.1 | $832k | -90% | 183k | 4.54 |
|
| Dbv Technologies S A Sponsored Adr (DBVT) | 0.0 | $69k | 93k | 0.75 |
|
Past Filings by Commodore Capital
SEC 13F filings are viewable for Commodore Capital going back to 2020
- Commodore Capital 2024 Q1 filed May 15, 2024
- Commodore Capital 2023 Q4 filed Feb. 14, 2024
- Commodore Capital 2023 Q4 restated filed Feb. 14, 2024
- Commodore Capital 2023 Q3 filed Nov. 14, 2023
- Commodore Capital 2023 Q2 filed Aug. 14, 2023
- Commodore Capital 2023 Q1 filed May 15, 2023
- Commodore Capital 2022 Q4 filed Feb. 14, 2023
- Commodore Capital 2022 Q3 filed Nov. 14, 2022
- Commodore Capital 2022 Q2 filed Aug. 15, 2022
- Commodore Capital 2022 Q1 filed May 16, 2022
- Commodore Capital 2021 Q4 filed Feb. 14, 2022
- Commodore Capital 2021 Q3 filed Nov. 15, 2021
- Commodore Capital 2021 Q1 restated filed Oct. 14, 2021
- Commodore Capital 2021 Q2 restated filed Oct. 14, 2021
- Commodore Capital 2021 Q2 filed Aug. 16, 2021
- Commodore Capital 2021 Q1 filed May 17, 2021